Baseline characteristics | Radiographic progression results | ||||
---|---|---|---|---|---|
Cohort | Numbera | Disease duration, yearsb | mSASSS valueb | Mean mSASSS change from baseline to year 2b | Between-cohort Pvalue |
Etanercept [2] | 257 | 10 ± 8.5 | 16 ± 18.3 | 0.9 ± 2.5 | 0.996 |
OASIS | 175 | 11 ± 8.5 | 14 ± 17.6 | 1.0 ± 3.2 | |
Infliximab [3] | 156 | 10.2 ± 8.7 | 17.7 ± 17.9 | 0.9 ± 2.6 | 0.541 |
OASIS | 165 | 11.3 ± 8.6 | 15.8 ± 18.1 | 1.0 ± 3.2 | |
Adalimumab | 307 | 11.2 ± 9.3 | 19.8 ± 19.3 | 0.8 ± 2.6 | 0.771 |
OASIS | 169 | 11.3 ± 8.6 | 15.8 ± 17.6 | 0.9 ± 3.3 |